Fig. 1 · Structure

Documents & Downloads

PD 150606

Cat. No. A15306 CAS 179528-45-1

Non-peptide calpain inhibitor

PD 150606 is a cell-permeable, non-competitive, selective, non-peptide Ca2+ dependent calpain inhibitor for calpain-1 and for calpain-2 directed towards the Ca2+ binding sites of calpain.

In Stock

Publications for PD 150606

1 publication citing this product

  1. Hisamatsu Y, .et al. , Bioconjug Chem, 2017, Feb 15;28(2):507-523 PMID: 28032992

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

PD150606 inhibited purified μ- and m-calpain in the original biochemical assays, with reported apparent Ki values of 0.21 ± 0.01 µM and 0.37 ± 0.03 µM, respectively (mean ± SEM). These are assay-specific historical estimates; the measured comparator profile does not establish exclusive calpain selectivity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

PD 150606 Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of PD 150606 from 2 published references.

PD 150606 In Vitro Studies

In intact SH-SY5Y cells, 10 µM PD150606 reduced maitotoxin-stimulated SLLVY-AMC cleavage. The saturated analog PD145305 did not inhibit at 50 µM. This experiment measures substrate cleavage rather than cell survival or exclusive target engagement. [1]

Historical biochemical inhibition profile

Biochemical assay · Purified human erythrocyte μ-calpain and rabbit skeletal-muscle m-calpain; comparator proteases and calcineurin/calmodulin assay. [1]

Table 1 reports submicromolar apparent Ki values for both calpains under the original assay conditions. The same panel shows weaker inhibition of cathepsin B and calmodulin-stimulated calcineurin. These historical assay estimates do not establish exclusive target selectivity or a binding site.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
μ-Calpain casein hydrolysisApparent Ki 0.21 ± 0.01 µM (6)[1]
m-Calpain casein hydrolysisApparent Ki 0.37 ± 0.03 µM (4)[1]
Cathepsin B activityApparent Ki 127.8 ± 9.2 µM (4)[1]
Calmodulin-stimulated component of calcineurin activityApparent Ki 12.98 ± 0.47 µM (4)[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response inhibition assays; the individual casein-assay dose series is not enumerated.
Exposure duration
Calpain casein assay: 60 min at 25 °C.
Method
Casein (0.5 mg/mL), 20 mM DTT, 50 mM Tris-HCl pH 7.4, purified μ-calpain (0.01 unit) or m-calpain (about 0.08–0.12 µg), 4 mM CaCl2; absorbance at 595 nm. Comparator assays used their separately described conditions.
Reported limits
Vehicle not specified for these assays. Table n is reproduced without assigning a biological-replicate definition. Ki values are endpoints, not treatment concentrations.
Methods and source locations

Compound reported in the paper: PD150606; Compound label in the paper: PD150606 (Fig. 1)

Original PD150606 results only; no salt conversion or Adooq batch validation.

Table 1, p. 6690; Protease Assays and Kinetic Studies, pp. 6687–6688; selectivity results p. 6689

μ-Calpain casein hydrolysis: Casein assay; apparent Ki calculated from IC50 using the cited Cheng–Prusoff method; mean ± SEM, paper n in parentheses. — Table 1, p. 6690; Protease Assays and Kinetic Studies, pp. 6687–6688

m-Calpain casein hydrolysis: Same reported casein-assay calculation; mean ± SEM, paper n in parentheses. — Table 1, p. 6690; Protease Assays and Kinetic Studies, p. 6687

Cathepsin B activity: Fluorogenic Cbz-Arg-Arg-MNA assay, pH 5.5; mean ± SEM, paper n in parentheses. Authors caution that high-concentration fluorescence quenching may contribute. — Table 1, p. 6690; methods p. 6687; Results p. 6689

Calmodulin-stimulated component of calcineurin activity: p-Nitrophenyl phosphate assay; calmodulin-stimulated component calculated separately from basal activity; mean ± SEM, paper n in parentheses. — Table 1, p. 6690; methods pp. 6687–6688

Reduced fluorogenic substrate cleavage in intact neuroblastoma cells

Cell-based study · Human SH-SY5Y neuroblastoma cells (SY5Y); maitotoxin-stimulated intact-cell SLLVY-AMC hydrolysis. [1]

PD150606 reduced maitotoxin-stimulated substrate hydrolysis. CalpInh-I and PD151746 were active comparators; inactive analog PD145305 did not inhibit at the tested concentration. This is a substrate-cleavage endpoint, not a cell-survival assay or proof of exclusive calpain engagement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Maitotoxin-stimulated SLLVY-AMC hydrolysisSubstrate hydrolysis Reduced with 10 µM PD150606 versus maitotoxin alone; P < 0.0001; n = 3, mean ± SEM.[1]
Comparator response in the same intact-cell assayActive/inactive controls CalpInh-I and PD151746 (each 10 µM) reduced hydrolysis; PD145305 (50 µM) did not inhibit.[1]

Literature-Reported Treatment Conditions

Treatment concentration
PD150606 10 µM; maitotoxin 0.1 nM; SLLVY-AMC 80 µM.
Exposure duration
1 h inhibitor pretreatment. Fig. 5 reports the readout at 60 min after substrate/stimulus addition.
Method
Cells made serum-free before inhibitor pretreatment; intact-cell fluorescence measured at room temperature.
Co-treatment
Maitotoxin stimulation; comparator inhibitors tested in separate conditions.
Reported limits
Vehicle not specified. Shared methods describe recording up to 120 min; the adopted Fig. 5 endpoint is explicitly 60 min. Caption n = 3 does not define the replicate unit.
Methods and source locations

Compound reported in the paper: PD150606; Compound label in the paper: PD150606

Original PD150606 results only; no salt conversion or Adooq batch validation.

Cell calpain methods p. 6688; intact-cell results p. 6690; Fig. 5/caption p. 6691

Maitotoxin-stimulated SLLVY-AMC hydrolysis: Fluorescence of liberated AMC at 60 min in Fig. 5; Student’s t-test. No percentage inferred from bar heights. — Fig. 5 and caption, p. 6691; results p. 6690; cell methods p. 6688

Comparator response in the same intact-cell assay: Same Fig. 5 design; untreated and maitotoxin-only groups included. PD145305 is a distinct saturated analog. — Fig. 5, p. 6691; results p. 6690; Fig. 1, p. 6689

PD 150606 In Vivo Studies

In a mouse transverse aortic constriction model, PD150606 pretreatment (8 µmole/kg intraperitoneally, 30 min before surgery) reduced the lung calpain-activity readout and preserved VE-cadherin, p120-catenin and β-catenin abundance at 24 h relative to TAC vehicle controls. The drug experiment addresses tissue proteolysis endpoints and does not establish isoform-specific action. [2]

Lung proteolysis endpoints after transverse aortic constriction

Animal study · Piezo1fl/fl mice subjected to transverse aortic constriction (TAC) or sham surgery; lung lysates at 24 h. Shared methods describe both sexes, 8–12 weeks old. [2]

Preoperative PD150606 lowered the TAC-associated lung calpain-activity readout and preserved junctional-protein abundance relative to vehicle-treated TAC mice. These tissue endpoints do not establish a direct effect on vascular leakage by PD150606 or distinguish calpain isoforms.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Relative lung calpain activity at 24 h after TACRelative activity Lower with PD150606 than TAC vehicle; P ≤ 0.05 (Fig. 4B).[2]
Lung VE-cadherin, p120-catenin and β-catenin abundanceProtein abundance TAC-associated decreases were prevented in the PD150606 groups.[2]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
TAC + PD150606
8 µmole/kg
TAC + vehicle; sham groupsLower activity and preserved junctional proteins at 24 h relative to TAC vehicle.[2]
TAC + vehicleSham + vehicleIncreased calpain activity and reduced junctional protein abundance.[2]
Sham + PD150606
8 µmole/kg
Sham + vehicleDrug-treated sham comparison included; no numerical baseline effect inferred.[2]
Sham + vehicleTAC + vehicleSurgical baseline comparison.[2]
TAC + PD150606
Model: Piezo1fl/fl mice; TAC
Route: Intraperitoneal
Frequency: Preoperative administration described; repeat dosing not specified.
Treatment course: 30 min before surgery; lung endpoint 24 h afterward.
Reported limits: Vehicle formulation and explicit animal n not specified; no dose conversion.
TAC + vehicle
Model: Piezo1fl/fl mice; TAC
Treatment course: Lung endpoint 24 h after surgery.
Reported limits: Vehicle formulation and explicit animal n not specified; no dose conversion.
Sham + PD150606
Model: Piezo1fl/fl mice; sham surgery
Route: Intraperitoneal
Frequency: Preoperative administration described; repeat dosing not specified.
Treatment course: 30 min before surgery; lung endpoint 24 h afterward.
Reported limits: Vehicle formulation and explicit animal n not specified; no dose conversion.
Sham + vehicle
Model: Piezo1fl/fl mice; sham surgery
Treatment course: Lung endpoint 24 h after surgery.
Reported limits: Vehicle formulation and explicit animal n not specified; no dose conversion.
Methods and source locations

Compound reported in the paper: PD150606; Compound label in the paper: PD150606

Reported PD150606 pretreatment in this mouse model; no extrapolation to Adooq lot performance or therapeutic efficacy.

Results: Piezo1-Induced Calpain Activation Disrupts VE-Cadherin Homotypic Interaction; Fig. 4B–D; SI pp. 2–4,7

Relative lung calpain activity at 24 h after TAC: Ac-LLY-AFC cleavage in lung homogenates using Abcam ab65308; 100 µg protein, 60 min at 37 °C; fluorescence normalized to protein. Mean ± SEM shown; no numerical fold-change inferred. — Fig. 4B and caption; SI p. 7, Calpain activity

Lung VE-cadherin, p120-catenin and β-catenin abundance: Whole-lung Western blots and β-actin-normalized densitometry; qualitative direction verified in Fig. 4C–D. Mean ± SEM; exact values not tabulated in the read source. — Fig. 4C–D and caption; SI p. 7, Western blotting of whole lung lysates

TAC + PD150606 · Fig. 4B–D/caption; SI p. 4, TAC; p. 7, activity and whole-lung Western blotting

TAC + vehicle · Fig. 4B–D/caption; SI p. 4, TAC; p. 7, activity and whole-lung Western blotting

Sham + PD150606 · Fig. 4B–D/caption; SI p. 4, TAC; p. 7, activity and whole-lung Western blotting

Sham + vehicle · Fig. 4B–D/caption; SI p. 4, TAC; p. 7, activity and whole-lung Western blotting

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 179528-45-1
Applications Non-peptide calpain inhibitor
Formula C9H7IO2S
Molecular Weight 306.12
SMILES
C1=CC(=CC=C1C=C(C(=O)O)S)I

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

PD 150606 Research References

  1. [1] Wang KK, Nath R, Posner A, et al. An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective. Proceedings of the National Academy of Sciences of the United States of America (1996). PMID: 8692879 DOI: 10.1073/pnas.93.13.6687 Source material
  2. [2] Friedrich EE, Hong Z, Xiong S, et al. Endothelial cell Piezo1 mediates pressure-induced lung vascular hyperpermeability via disruption of adherens junctions. Proceedings of the National Academy of Sciences of the United States of America (2019). PMID: 31186359 DOI: 10.1073/pnas.1902165116 Source material

Publications

1 publication citing this product

  1. Hisamatsu Y, .et al. , Bioconjug Chem, 2017, Feb 15;28(2):507-523 PMID: 28032992

Added to your cart

View Cart Checkout
Loading...